A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- Registration Number
- NCT06662786
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Have histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer. Participants must have unresectable or metastatic disease
- Be diagnosed to have Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type (WT) tumor as determined by local testing
- Must agree to the submission of fresh tumor tissue
- Have measurable disease according to RECIST v1.1
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
- Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: (a) amivantamab or cetuximab, (b) any component of mFOLFOX6 and, (c) any component of FOLFIRI
- Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status and human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor
- Has prior exposure to any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B: Cetuximab in Combination With Chemotherapy Leucovorin calcium/Levoleucovorin Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab in Combination With Chemotherapy Amivantamab Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab in Combination With Chemotherapy 5-fluorouracil Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab in Combination With Chemotherapy Leucovorin calcium/Levoleucovorin Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab in Combination With Chemotherapy Oxaliplatin Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab in Combination With Chemotherapy Irinotecan Hydrochloride Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab in Combination With Chemotherapy Cetuximab Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab in Combination With Chemotherapy 5-fluorouracil Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab in Combination With Chemotherapy Oxaliplatin Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab in Combination With Chemotherapy Irinotecan Hydrochloride Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Up to 4 years and 2 months PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v) 1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by Investigator Up to 7 Years 3 Months PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by the investigator.
Objective Response Rate (ORR) as Assessed by Investigator Up to 7 Years 3 Months ORR is defined as the percentage of randomized participants achieving complete CR or PR, as assessed by the investigator.
Overall Survival (OS) Up to 7 Years 3 Months OS is defined as the time from the date of randomization to the date of participant's death due to any cause. Any participant not known to have died at the time of analysis will be censored based on the last recorded date on which the participant was known to be alive.
Objective Response Rate (ORR) as Assessed by BICR Up to 7 Years 3 Months ORR is defined as the percentage of randomized participants achieving complete response (CR) or partial response (PR), as determined by BICR using RECIST v1.1 criteria.
Duration of Response (DOR) as Assessed by BICR Up to 7 Years 3 Months DOR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR, as assessed by BICR using RECIST v1.1 criteria.
Duration of Response (DOR) as Assessed Investigator Up to 7 Years 3 Months DOR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR, as assessed by the investigator.
Progression-free Survival After Subsequent Therapy (PFS2) Up to 7 Years 3 Months PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.
Disease Control Rate (DCR) as Assessed by BICR Up to 7 Years 3 Months DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with minimum duration of 7 weeks) as assessed by BICR using RECIST v1.1 criteria.
Disease Control Rate (DCR) as Assessed by Investigator Up to 7 Years 3 Months DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with minimum duration of 7 weeks) as assessed by the investigator.
Time to Treatment Failure Up to 7 Years 3 Months Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy.
Curative Resection (R0) Rate Up to 7 Years 3 Months Curative resection (R0) rate is defined as the percentage of participants (or participants with limited disease at baseline) who underwent curative surgery.
Number of Participants with Adverse Events (AEs) by Severity Up to 7 Years 3 Months An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. AE severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) v5.0. by using the standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.
Number of Participants with Abnormalities in Laboratory Values Up to 7 Years 3 Months Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score From Baseline up to 7 Years 3 Months The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30 Up to 7 Years 3 Months The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptom.
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer Module 29 (EORTC-QLQ-C30) Score From Baseline up to 7 Years 3 Months The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-CR29 Up to 7 Years 3 Months The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.
Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score Up to 7 Years 3 Months The EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "not at all" to 4 "very much." Higher scores indicate severe side effects.
Trial Locations
- Locations (178)
Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
Universitatsklinikum Ulm
🇩🇪Ulm, Germany
Semmelweis Egyetem
ðŸ‡ðŸ‡ºBudapest, Hungary
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
Hospital Canselor Tuanku Muhriz UKM
🇲🇾Cheras, Malaysia
Hospital Pulau Pinang
🇲🇾Georgetown, Malaysia
Hospital Raja Permaisuri Bainun
🇲🇾Ipoh, Malaysia
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Hospital Umum Sarawak
🇲🇾Kuching, Malaysia
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. Ramon Y Cajal
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
Sahlgrenska University Hospital
🇸🇪Goteborg, Sweden
Skanes universitetssjukhus
🇸🇪Lund, Sweden
Sodersjukhuset
🇸🇪Stockholm, Sweden
Adana City Hospital
🇹🇷Adana, Turkey
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
Huizhou Central People's Hospital
🇨🇳Huizhou, China
St. Bernard's Medical Center
🇺🇸Jonesboro, Arkansas, United States
CBCC Global Research
🇺🇸Bakersfield, California, United States
Cancer and Blood Specialty Clinic
🇺🇸Los Alamitos, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Providence Medical Foundation
🇺🇸Santa Rosa, California, United States
Torrance Memorial Physicians Network
🇺🇸Torrance, California, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States
Georgetown Univ Medical Center Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Grady Memorial Hospital
🇺🇸Atlanta, Georgia, United States
Winship Cancer Institute Emory University
🇺🇸Atlanta, Georgia, United States
Fort Wayne Medical Oncology & Hematology
🇺🇸Fort Wayne, Indiana, United States
MedStar Franklin Square Medical Center
🇺🇸Baltimore, Maryland, United States
Hattiesburg Clinic
🇺🇸Hattiesburg, Mississippi, United States
Washington University School Of Medicine
🇺🇸Saint Louis, Missouri, United States
Nebraska Cancer Specialists Midwest Cancer Center
🇺🇸Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
B P Poddar Hospital and Medical research Limited
🇮🇳Kolkata, India
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hopital de Jolimont
🇧🇪Haine Saint Paul La Louviere, Belgium
Cleveland Clinic Cancer Center Mansfield
🇺🇸Mansfield, Ohio, United States
Rutgers Cancer Institute
🇺🇸New Brunswick, New Jersey, United States
University of New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Mount Sinai
🇺🇸New York, New York, United States
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
🇺🇸New York, New York, United States
New York Cancer and Blood Specialists
🇺🇸Shirley, New York, United States
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion
🇺🇸Cleveland, Ohio, United States
Taussig Cancer Insititute Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic Cancer Center Independence Family Health Center
🇺🇸Independence, Ohio, United States
Cleveland Clinic Cancer Center Hillcrest Hospital
🇺🇸Mayfield Heights, Ohio, United States
Cleveland Clinic Cancer Centers Sandusky
🇺🇸Sandusky, Ohio, United States
Cleveland Clinic Cancer Center Strongsville
🇺🇸Strongsville, Ohio, United States
Cleveland Clinic Cancer Center South Pointe Hospital
🇺🇸Warrensville Heights, Ohio, United States
Wooster Milltown Specialty and Surgery Center
🇺🇸Wooster, Ohio, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Baylor Scott and White Health
🇺🇸Temple, Texas, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Az Groeninge
🇧🇪Kortrijk, Belgium
Universitair Ziekenhuis Leuven
🇧🇪Leuven, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Fundacao Universidade de Caxias do Sul
🇧🇷Caxias do Sul, Brazil
Hospital Santa Izabel Santa Casa de Misericordia da Bahia
🇧🇷Salvador, Brazil
Clinica de Hematologia e Oncologia Viver Ltda
🇧🇷Santa Maria, Brazil
Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base
🇧🇷Sao Jose do Rio Preto, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
🇧🇷Vitoria, Brazil
Arthur J E Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Peking University First Hospital
🇨🇳Beijing, China
Beijing Friendship Hospital Capital Medical University
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
The First Bethune Hospital of Jilin University
🇨🇳Changchun, China
Klinikum der Universitaet Muenchen
🇩🇪Munich, Germany
The Sixth Affiliated Hospital Sun Yat sen University
🇨🇳Guangzhou, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
The First Affiliated Hospital Zhejiang University College of Medicine
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
The First Affiliated Hospital of NanChang University
🇨🇳Nanchang, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
West China Hospital of Sichuan University
🇨🇳Sichuan, China
First Hospital of Shanxi Medical University
🇨🇳Taiyuan, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, France
Hopital Claude Huriez
🇫🇷Lille, France
Hopital Prive Jean Mermoz
🇫🇷Lyon, France
Institut du Cancer de Montpellier
🇫🇷Montpellier, France
CHU Nantes
🇫🇷Nantes Cedex 1, France
Hopital Saint Antoine
🇫🇷Paris, France
Hopital Haut Leveque
🇫🇷Pessac, France
CHU De Poitiers
🇫🇷Poitiers Cedex, France
Gustave Roussy
🇫🇷Villejuif, France
Charite Universitatsmedizin Berlin Campus Virchow Klinikum
🇩🇪Berlin, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
🇩🇪Dresden, Germany
Essen University Hospital
🇩🇪Essen, Germany
Krankenhaus NorthWest
🇩🇪Frankfurt am Main, Germany
Praxis fur interdisziplinare Onkologie & Hamatologie GbR
🇩🇪Freiburg, Germany
Asklepios Klinik Altona
🇩🇪Hamburg, Germany
Markhot Ferenc Oktatokorhaz es Rendelointezet
ðŸ‡ðŸ‡ºEger, Hungary
Pecsi Tudomanyegyetem
ðŸ‡ðŸ‡ºPecs, Hungary
Rajiv Gandhi Cancer Institute and Research Centre
🇮🇳Delhi, India
Tata Memorial Hospital
🇮🇳Mumbai, India
Deenanath Mangeshkar Hospital and Research Centre
🇮🇳Pune, India
Yitzhak Shamir Medical Center
🇮🇱Beer Yaakov, Israel
Rambam Medical Center
🇮🇱Haifa, Israel
Hadassah University Hospita Ein Kerem
🇮🇱Jerusalem, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv Yafo, Israel
Assuta MC
🇮🇱Tel Aviv Yafo, Israel
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Istituto Dei Tumori Di Milano
🇮🇹Milano, Italy
Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Italy
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Aichi Cancer Center
🇯🇵Nagoya Shi, Japan
Osaka International Cancer Institute
🇯🇵Osaka City, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka-Shi, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Osaka University Hospital
🇯🇵Suita, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Marys Hospital
🇰🇷Seoul, Korea, Republic of
National Cancer Institute
🇲🇾Putrajaya, Malaysia
Meander Medisch Centrum
🇳🇱Amersfoort, Netherlands
Radboud University Medical Center
🇳🇱Nijmegen, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
Elisabeth-TweeSteden Ziekenhuis
🇳🇱Tilburg, Netherlands
Wojewodzki Szpital Specjalistyczny
🇵🇱Biala Podlaska, Poland
Bialostockie Centrum Onkologii im Marii Sklodowskiej Curie w Bialymstoku
🇵🇱Bialystok, Poland
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
🇵🇱Brzozow, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
🇵🇱Gliwice, Poland
Instytut Centrum Zdrowia Matki Polki
🇵🇱Lodz, Poland
SPZOZ Ministerstwa Spraw Wewnetrznych z Warminsko Mazurskim Centrum Onkologii w Olsztynie
🇵🇱Olsztyn, Poland
SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego
🇵🇱Opole, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie
🇵🇱Warszawa, Poland
Pan American Center for Oncology Trials LLC
🇵🇷Barrio Monacillos, Puerto Rico
Karolinska Universitetssjukhuset
🇸🇪Stockholm, Sweden
Uppsala University
🇸🇪Uppsala, Sweden
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Gulhane Egitim ve Arastirma Hastanesi
🇹🇷Ankara, Turkey
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
🇹🇷Ankara, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Bakirkoy Training and Research Hospital
🇹🇷Istanbul, Turkey
Marmara University Pendik Training Hospital
🇹🇷İstanbul, Turkey
Necmettin Erbakan University Meram Medical Faculty
🇹🇷Konya, Turkey
Sakarya University Training and Research Hospital
🇹🇷Sakarya, Turkey
Addenbrooke's Hospital
🇬🇧Cambridge, United Kingdom
Western General Hospital
🇬🇧Edinburgh, United Kingdom
Castle Hill Hospital
🇬🇧Hull, United Kingdom
St James University Hospital
🇬🇧Leeds, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
University College Hospital
🇬🇧London, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, United Kingdom
Royal Marsden Hospital (Sutton)
🇬🇧Sutton, United Kingdom